(2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]q uinazolinyl

Details (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]q uinazolinyl (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]q uinazolinyl

1985-11-14

1987-06-02

Daus, Donald G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

260544N, 514267, 544115, 544250, 544165, 544387, 546146, 546164, 546166, 546226, 548491, 548540, 560 23, 562434, 564142, 564166, A61K 31505, C07D48704

Patent

active

046704345

ABSTRACT:
This invention relates to compounds of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof wherein the various substituents are defined herein. These compounds are cyclic AMP phosphodiesterase inhibitors useful as antithrombotic and inotropic agents in mammals.

REFERENCES:
patent: Re31617 (1984-06-01), Beverung, Jr. et al.
patent: 3932407 (1976-01-01), Beverung, Jr. et al.
patent: 4070470 (1978-01-01), Nakagawa et al.
patent: 4313947 (1982-02-01), Nakagawa et al.
patent: 4490371 (1984-12-01), Jones et al.
patent: 4596806 (1986-06-01), Ishikawa et al.
European Journal of Medicinal Chemistry, 1982-17, No. 6d, pp. 547-556 by Keinzle et al.
Journal of Pharmacology and Experimental Therapeutics, vol. 211, No. (1979), pp. 26-30 by Hidaka et al.

Affiliated with

Also associated with

Rating

(2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]q uinazolinyl does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]q uinazolinyl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]q uinazolinyl will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-613763